Cost-Effectiveness of 2023-2024 COVID-19 Vaccination in US Adults.

ABSTRACT:

Importance

Evidence is needed on the economic favorability of a 2023-2024 COVID-19 vaccination program to support policy decisions on recommendations for COVID-19 vaccination.

Objective

To measure the cost-effectiveness of vaccination with a 2023-2024 COVID-19 mRNA vaccine in adults aged 18 years or older compared with no updated vaccination (with a 2023-2024 vaccine).

Design, setting, and participants

This decision analytic modeling study used a simulation model to compare outcomes for hypothetical cohorts of vaccinated and unvaccinated, immunocompetent adults stratified by age (18-49 years, 50-64 years, and ≥65 years). Parameters were drawn from primary and published data to represent characteristics of the US adult population. The interventions included vaccination

SUBMITTER: Prosser LA 

PROVIDER: S-EPMC12332627 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature